GlassScriptPhysician profile
Fadi A Safi
NPI 1649436429
$6,901.85
in general payments reported to CMS, 2019-2025
22 companies · $5,651 in 2025
The $5,651 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $93.09 · 2021: $230 · 2022: $31.86 · 2023: $399 · 2024: $320 · 2025: $5,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,026 · Travel and Lodging: $1,200 · Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,025.70 |
| Travel and Lodging | $1,200.27 |
| Food and Beverage | $1,143.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,448.82 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.92 | 2020-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $147.85 | 2019-2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $143.31 | 2025 | General - Pain Management |
| Pulmonx Corporation | $125.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $106.89 | 2023 | Acthar |
| Grifols USA, LLC | $77.20 | 2023-2025 | Prolastin-C Liquid |
| Insmed, INC. | $67.93 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $67.36 | 2019-2024 | Trelegy Ellipta |
| Baxter Healthcare | $54.52 | 2025 | Hillrom - Vest System Model 105 Home Care |
| La Jolla Pharmaceutical Company | $46.80 | 2021-2023 | Giapreza |
| Pfizer INC. | $36.14 | 2024-2025 | |
| Electromed, INC. | $31.56 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $28.18 | 2025 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Zerbaxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.65 | 2025 | |
| United Therapeutics Corporation | $23.88 | 2025 | Tyvaso |
| Inspire Medical Systems, INC. | $22.75 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $20.89 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2020 | |
| Amgen INC. | $13.53 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Safi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.